Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 22,439 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pathologic Processes Clear all
Recruiting Not applicable Interventional

BLOOM: Pragmatic Feasibility Trial

NCT07287332
View directory record Official record
Conditions
Sepsis, Infection
Interventions
Up-front individualized dosing algorithm, Usual Care
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 21, 2026, 7:28 AM EDT
Completed Not applicable Interventional Results available

Closed-Loop Fluid Administration System Using Hemodynamic Monitors

NCT02020863
View directory record Official record
Conditions
Intraoperative Volume Status, Postoperative Complications
Interventions
Closed Loop
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 27, 2016 · Synced Oct 21, 2026, 7:28 AM EDT
Completed Not applicable Interventional

Study to Evaluate the Effectiveness of the Initial Specimen Diversion Device

NCT02102087
View directory record Official record
Conditions
Septicemia
Interventions
Initial Specimen Diversion Device (ISDD), Lab standard practice (LSP)
Device
Lead sponsor
Magnolia Medical Technologies, Inc.
Industry
Eligibility
19 Years and older
Enrollment
971 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 21, 2026, 7:28 AM EDT
Recruiting No phase listed Observational

Precision Medicine Approaches to Renal Osteodystrophy

NCT05880914
View directory record Official record
Conditions
Renal Osteodystrophy, Chronic Kidney Diseases, CKD-MBD, Bone Turnover Rate Disorder, Secondary Hyperparathyroidism
Interventions
miRNAseq analysis, Standard treatment for bone disorder
Procedure · Drug
Lead sponsor
Thomas Nickolas
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 21, 2026, 7:28 AM EDT
Completed Phase 3 Interventional

Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease

NCT00003414
View directory record Official record
Conditions
Graft Versus Host Disease, Lymphoma
Interventions
aldesleukin, recombinant interferon gamma, busulfan, cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2015 · Synced Oct 21, 2026, 7:28 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

NCT00003816
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Nonmalignant Neoplasm, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
anti-thymocyte globulin, busulfan, carboplatin, cyclophosphamide, etoposide, fludarabine phosphate, melphalan, thiotepa, total-body irradiation
Biological · Drug · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
4 Years to 70 Years
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2019
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 21, 2026, 7:28 AM EDT
Terminated Phase 2 Interventional Results available

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

NCT02978716
View directory record Official record
Conditions
Triple-Negative Breast Neoplasms, Breast Neoplasm, Breast Cancer, Triple-Negative Breast Cancer
Interventions
Trilaciclib, Gemcitabine, Carboplatin
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
35
States / cities
Tucson, Arizona • Burbank, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 21, 2026, 7:28 AM EDT
Terminated Phase 2 Interventional

A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

NCT06682806
View directory record Official record
Conditions
Advanced Solid Tumor, Esophageal Cancer, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation
Interventions
PRT3789, pembrolizumab
Drug
Lead sponsor
Prelude Therapeutics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
West Palm Beach, Florida • Detroit, Michigan • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 21, 2026, 7:28 AM EDT
Completed Phase 2 Interventional

Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment

NCT00680342
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Silymarin, Placebo
Drug · Other
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Oct 21, 2026, 7:28 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

NCT06566742
View directory record Official record
Conditions
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Clonal Cytopenia of Undetermined Significance
Interventions
Olutasidenib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
2
States / cities
Miami, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 21, 2026, 7:28 AM EDT
Recruiting Not applicable Interventional

Optimizing Recovery in Trauma Patients by Integrating Enhanced Nutrition Delivery

NCT06521086
View directory record Official record
Conditions
Trauma, Critical Illness
Interventions
Nutrition Supplements - Fresubin KCAL Drinks
Dietary Supplement
Lead sponsor
Duke University
Other
Eligibility
45 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 21, 2026, 7:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma

NCT05458869
View directory record Official record
Conditions
Cervical Carcinoma, Human Papillomavirus Infection
Interventions
HPV Self-Collection, Interview, Survey Administration
Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
25 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 21, 2026, 7:28 AM EDT
Recruiting Phase 3 Interventional

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566
View directory record Official record
Conditions
Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Metastatic Non Small Cell Lung Cancer, Lung Cancer
Interventions
PF-08634404, Pembrolizumab, Chemotherapy Regimen 1, Chemotherapy Regimen 2
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
226
States / cities
Bullhead City, Arizona • Chandler, Arizona • Gilbert, Arizona + 164 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 7:28 AM EDT
Completed Not applicable Interventional

Non-invasive Diagnosis of Portal Hypertension With Acoustic Radiation Force Impulse (ARFI)

NCT01644656
View directory record Official record
Conditions
Portal Hypertension, Chronic Liver Disease
Interventions
ARFI ultrasound
Device
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 85 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 21, 2026, 7:28 AM EDT
Completed Not applicable Interventional

Shear and Pressure Reducing Insoles for the Diabetic Foot

NCT00499356
View directory record Official record
Conditions
Diabetes, Ulceration, Amputation, Foot Deformity, Neuropathy
Interventions
pressure reducing insole, GlideSoft®
Device
Lead sponsor
Diabetica Solutions Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2007 · Synced Oct 21, 2026, 7:28 AM EDT
Completed No phase listed Observational

Analyzing Lung Tissue in People With and Without Chronic Obstructive Pulmonary Disease Who Are Undergoing Lung Transplantation

NCT00756522
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
There is no intervention. Study is observational.
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 21, 2026, 7:28 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

NCT03067129
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation
Drug
Lead sponsor
AbbVie
Industry
Eligibility
3 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
15
States / cities
San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 21, 2026, 7:28 AM EDT
Completed Phase 2 Interventional Results available

Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT00439231
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma
Interventions
Lenalidomide
Drug
Lead sponsor
Georg Aue, M.D.
NIH
Eligibility
21 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 21, 2026, 7:28 AM EDT
Terminated Phase 2 Interventional Results available

Early Metabolic Resuscitation for Septic Shock

NCT03895853
View directory record Official record
Conditions
Multiple Organ Failure, Septic Shock, Severe Sepsis
Interventions
Best Practice, early metabolic resuscitation
Other · Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 21, 2026, 7:28 AM EDT
Completed Not applicable Interventional

Post-operative Lite Run Study

NCT03135145
View directory record Official record
Conditions
Cerebral Palsy, Neurologic Disorder, Chromosome Abnormality, Spina Bifida
Interventions
Lite Run Gait Trainer, Usual Treatments
Device · Other
Lead sponsor
Gillette Children's Specialty Healthcare
Other
Eligibility
4 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 21, 2026, 7:28 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

NCT04596995
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 21, 2026, 7:28 AM EDT
Completed Phase 1 Interventional

Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection

NCT00565539
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
PEGylated recombinant interleukin 29 (PEG-rIL-29)
Drug
Lead sponsor
ZymoGenetics
Industry
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Chicago, Illinois • Detroit, Michigan • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2009 · Synced Oct 21, 2026, 7:28 AM EDT
Approved For Marketing No phase listed Expanded access

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

NCT01833039
View directory record Official record
Conditions
Relapsed or Refractory Mantle Cell Lymphoma
Interventions
Ibrutinib
Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 21, 2026, 7:28 AM EDT
Completed Phase 2 Interventional

New Medications to Treat Alcohol Dependence

NCT00223639
View directory record Official record
Conditions
Alcoholism
Interventions
Topiramate
Drug
Lead sponsor
Bankole Johnson
Other
Eligibility
21 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Oct 21, 2026, 7:28 AM EDT